Richard A. Larson, MD
Professor of Medicine, Section of Hematology/Oncology
Director of the Hematologic Malignancies Clinical Research Program
Chairman of the Leukemia Committee of the Cancer and Leukemia Group B
Dr. Richard A. Larson is a Professor of Medicine in the Section of Hematology/and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He received his medical degree from the Stanford University School of Medicine in 1977, and completed his postdoctoral training in internal medicine, hematology, and oncology at the University of Chicago. He was a Fellow of the Society of America and was granted a Clinical Oncology Career Development Award from the American Society. He has been a member of the faculty in the Section of Hematology/Oncology and the Comprehensive Cancer Center at the University of Chicago since 1983. He was Director of the Leukemia Clinical Research Program from 1983 to 2000, during which time he established the adult transplant program at the University of Chicago Medical Center in 1986. He is board certified in internal medicine, hematology, and medical oncology, and has served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.
In 1997, Dr. Larson was appointed chair of the Leukemia Committee of the Cancer and Leukemia Group B, where he directs a large portfolio of clinical trials and ancillary laboratory studies in acute and chronic leukemias and myeloma. He is a former councilor on the Executive Committee of the American Society of Hematology and a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Larson has published more than 300 papers, reviews, and book chapters on clinical and laboratory studies in human leukemias and, in addition, has served on the editorial boards of Blood, the Journal of Clinical Oncology, and Leukemia. He is a Section Editor for Leukemia of UpToDate.
Dr. Larson maintains an active clinical practice at the University of Chicago Medical Center, and his expertise is widely sought for consultations regarding leukemia and the myelodysplastic syndromes. He participates actively in the training of 22 fellows in hematology/oncology within the Department of Medicine. His current research interests include clinical trials in hematologic malignancies and, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the of therapy-related leukemias.
Selected Publications from 2010 – 2011
- Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 117:7007-7013, 2011.
- Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-807, 2011.
- Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349-1355, 2011.
- Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381, 2011.
- Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA; Cancer and Leukemia Group B. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 35:329-333, 2011.
- Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM.Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis 3:e2011019, 2011.
- Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116:5660-5669, 2010.
- O’Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 51:2240-2249, 2010.
- Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010.
- Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757, 2010.
- Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116:3622-3626, 2010.
- Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 285:32596-32605, 2010.
- Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28:4500-4506, 2010.
- Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood 116:2420-2428, 2010.
- Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-1421, 2010.
- Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010.
- Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 51:995-1006, 2010.
- Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010.
- Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010.
- Larson RA and Le Beau MM. Prognosis and therapy of therapy-related acute promyelocytic leukemia and other “good risk” acute myeloid leukemias.” Mediteranean J Hematol Inf Dis [in press], 2011.
- Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol 38:196-214, 2011.
- Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol 38:215-224, 2011.
- Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA, Le Beau MM. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact 184:50-57, 2010.
- Larson RA. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. Chem Biol Interact 184:21-25, 2010.
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010.
- “Acute myeloid leukemia – new therapeutic targets”
Invited Speaker for Highlights of ASH, American Society of Hematology
San Antonio, TX
- “FLT3-mutated acute myeloid leukemia – chemotherapy, transplantation, and kinase inhibitors”
Invited Speaker for the Cleveland Clinic Cancer Center Grand Rounds
- “Update on AML – Recent reports from the 2009 American Society of Hematology annual meeting.”
Invited Speaker at Samsung Hospital
- “FLT3-mutated acute myeloid leukemia – chemotherapy, transplantation, and kinase inhibitors” Invited Speaker at the Annual meeting of the Korean Society of Blood and Marrow Transplantation
- “Current and future management of chronic myeloid leukemia”
Invited Speaker at the Annual meeting of the Taiwan Society of Hematology and the Taiwan Society of Marrow Transplantation
- “Therapy-related myeloid neoplasm – a model for environmental cancer”
Invited Speaker at the Environmental & Occupational Health Sciences Institute, Rutgers, the State University of New Jersey
New Brunswick, NJ
- “Acute myeloid leukemia – new therapeutic targets”
Invited Speaker for Highlights of ASH in Latin America, American Society of Hematology
Rio de Janeiro, Brazil
- “Comparison of nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year”
Invited Speaker at the American Society of Clinical Oncology Annual Meeting
- “Overview of imatinib in CML”
Invited Speaker at the Asia Pacific Summit 2010
- “What can we learn from pharmacogenomics?”
Invited Speaker at the European LeukemiaNet Frontiers meeting: New Benchmarks in Leukemia
- “Tumor lysis syndrome”
Invited Speaker at the American Society of Nephrology Annual Meeting
- “Chronic myeloid leukemia – targeting a fatal disease”
Invited Speaker at Medicine Grand Rounds, Northwestern University
- “Management of Adult ALL: What is different?”
Invited Speaker at the 9th Conference on Evidence Based Management of Cancers in India, Tata Memorial Hospital
- “Translating leukemia lessons to solid tumors – Can we bridge the gap?”
Invited Speaker at the Hospital Day Oration, 70th Anniversary of Tata Memorial Hospital
- “Therapy of Ph+ Acute Lymphoblastic Leukemia”
Invited Speaker at the Acute Leukemia XIII International Symposium: Biology and Treatment Strategies
- “Prognosis and therapy when acute promyelocytic leukemia and other “good risk” acute myeloid leukemia occur as a therapy-related myeloid neoplasm”
Invited Speaker at the 4th International Symposium on Secondary Leukemia and Leukemogenesis